

SPRING 2016 | VOLUME 6, NUMBER 2

2016 Alliance Spring Group Meeting Convenes This Week



The **Alliance for the Clinical Trials in Oncology** will convene its 2016 Spring Group Meeting in Chicago, IL, **May 12-14**. Scientists, clinical research professionals, patient advocates and others interested in the latest developments in cancer research are expected to attend the four-day meeting at the Loews Chicago O'Hare Hotel in Rosemont, IL. Meeting attendees will select from **nearly 70 disease, modality, administrative and special sessions** to attend led by distinguished oncology researchers and clinical trials specialists from across the country.

[Read more about meeting highlights](#)

Alliance Online at Group Meeting

Share your meeting highlights with us!

Alliance on Twitter

@ALLIANCE_org

Alliance Spring Meeting Hashtag

#AllianceSprMtg2016

Alliance on Facebook

<https://www.facebook.com/AllianceForClinicalTrialsInOncology/>

Alliance Website

AllianceNCTN.Org

MEETINGS

2016 - Spring & Fall

- May 12-14 | Chicago

- November 2-4 | Chicago

2017 - Spring & Fall

- May 11-13 | Chicago

- November 2-5 | Chicago

ANNOUNCEMENTS

In Memoriam:

[Egbert C. Brown](#)

[Kathleen W. Rao, PhD](#)

[Alliance Welcomes New Staff](#)

Funding Opportunities:

[Cancer Control Pilot Project](#)

[Cancer Control Jr. Faculty Award](#)

[Cancer Care Delivery Research](#)

[Pilot Project Funds](#)

[RLS CALGB Achievement Award](#)

[Alliance Scholar](#)

Did You Know? There's a

[Searchable Listing of Published](#)

[Manuscripts + Abstracts on](#)

[Alliance Website](#)

Visit our website

Learn more about what's happening in the Alliance, visit the [Alliance website](#) today!



Stay Connected

Like us on Facebook 

IN THE SPOTLIGHT

Thirteen Years of Service for Co-Chairs of the Alliance Breast Committee

Follow us on [twitter](#)

[Join Our Mailing List!](#)



The **Board of Directors of the Alliance for Clinical Trials in Oncology** proudly acknowledge **Clifford A. Hudis, MD**, and **Eric P. Winer, MD**, for more than a decade of dedicated service to the Alliance Breast Committee. Both are among the nation's leading specialists in breast cancer treatment and experts in planning and executing trials to improve patient outcomes.

[Read more](#)

SPOTLIGHT ON TRIALS

CALGB 10603 (RATIFY) Study Results Lead to FDA Breakthrough Therapy Designation for Investigational Treatment for Newly-diagnosed FLT3-mutated AML

The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to midostaurin (PKC412), an investigational treatment for adults with newly-diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. The Breakthrough Therapy designation for midostaurin is primarily based upon the positive results from the CALGB 10603 (RATIFY) phase III clinical trial.

[Read more](#)

Alliance for Clinical Trials in Oncology